HGS shares triple on startling lupus success

Shares of Human Genome Sciences tripled today after the company reported positive data for its experimental lupus therapy, which has faced a long lineup of skeptics.

Researchers say that the data on Benlysta was positive for reducing symptoms of lupus, a bottom-line conclusion that was completely unexpected by many of the industry's top analysts. Earlier trials had proven a disappointment, and other lupus programs had foundered over the years.

The data was a tonic for HGS stock, which jumped to $10.40 on the news.

"We have met the criteria in this study for success," Thomas Watkins, Human Genome's president and chief executive, told reporters. "Now we need to do it a second time in the other study."

- read the story from Bloomberg

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.